Background
Metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to steatohepatitis (NASH), have become important health issues in obese subjects. In this study, we investigated the relationship between MetS and NASH in severely obese subjects.
Methods
A total of 111 non-alcoholic obese patients who underwent laparoscopic bariatric surgery (BMI 45.4 ± 5.7 kg/m2) were enrolled from February to September 2004 in a referral center in North Taiwan. MetS and its individual components were defined using the American Heart Association/National Heart, Lung, and Blood Institute criteria. Based on liver biopsy during surgery, subjects were classified into either having NASH or not. The relationship among NASH, adiponectin, insulin resistance, MetS and its individual components was examined using a multivariate logistic regression analysis.
Results
The prevalence of NASH and MetS in these subjects was 79.3% and 68.5%, respectively. Using a multivariate logistic regression analysis with NASH as the outcome variable, odds ratio (OR) of NASH for subjects with MetS versus without MetS was 2.96 (95% CI = 1.14–7.68) adjusted for age, gender, and BMI. Also, high blood pressure (OR = 2.97, 1.31–6.73) and high fasting glucose (OR = 2.94, 1.13–7.67) were independently associated with NASH after adjustment for age, gender, and BMI. Insulin resistance measured as HOMA-IR and serum adiponectin level were not significantly different between the NASH and non-NASH group.
Conclusion
MetS and NASH were common in severely obese Taiwanese adults. Presence of MetS, high blood pressure, and high fasting glucose was independently related to increased risk of NASH.The underlying mechanism deserves to be explored in the future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38.
Huang KC, Lin WY, Lee LT et al. Four anthropometric indices and cardiovascular risk factors in Taiwan. Int J Obes 2002; 26: 1060–8.
Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583–9.
Haffner SM, Valdez RA, Hazuda HP et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715–22.
Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16.
Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–50.
Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367–72.
Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.
Shen YH, Yang WS, Lee TH et al. Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res 2005; 13: 1238–45.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–S112.
Kojima S, Watanabe N Numata M et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954–61.
Clark JM, Brancati FL Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7.
Marceau P, Biron S, Hould F et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–7.
Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16: 1278–86.
Arun J, Clements RH, Lazenby AJ et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006;16:1351–8.
Harnois F, Msika S, Sabate JM et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 2006; 16: 183–8.
Palekar NA, Naus R, Larson SP et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26: 151–6.
Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52.
Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg 2006; 16: 1584–93.
Liang RJ, Wang HH, Lee WJ et al. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 2007; 17: 45–56.
Banner BF, Savas L, Zivny J et al. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am J Clin Pathol 2000; 114: 860–6.
Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74.
Abrams GA, Kunde SS, Lazenby AJ et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40: 475–83.
Lin WY, Lee LT, Chen CY et al. Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes 2002; 26: 1232–8.
WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–63.
Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes 1998; 22: 1164–71.
Chang CJ, Wu CH, Chang CS et al. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obes 2003; 27: 253–9.
Kleiner DE, Brunt E Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
Lee WJ, Wang W. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005; 15: 751–7.
Torgerson JS, Lindroos AK, Sjostrom CD et al. Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes Res 1997; 5: 105–14.
Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71–9.
Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310–5.
Ferrannini E, Haffner SM, Mitchell BD et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416–22.
Lin WY, Yang WS, Lee LT et al. Insulin resistance, obesity, and metabolic syndrome among non-diabetic pre- and post-menopausal women in North Taiwan. Int J Obes 2006; 14: 1654–61.
Hansel B, Giral P, Nobecourt E et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963–71.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96 :939–49.
Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175–83.
Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46–54.
Louthan MV, Barve S, McClain CJ et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147: 835–8.
Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100.
Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222–5.
Uno K, Katagiri H, Yamada T et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006; 312: 1656–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, HL., Lin, WY., Lee, LT. et al. Metabolic Syndrome Is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects. OBES SURG 17, 1457–1463 (2007). https://doi.org/10.1007/s11695-008-9423-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-008-9423-0